The Consensus Molecular Subtypes of Colorectal Cancer
By Justin Guinney, R. Dienstmann, Xin Wang, A. de Reyniès, A. Schlicker, Charlotte Soneson, L. Marisa, P. Roepman, G. Nyamundanda, P. Angelino and 30 more. Nature Medicine, 2015
4,640 citations recorded by the source corpus.
Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and drug responses. To resolve inconsistencies among the reported gene expression–based CRC classifications and facilitate clinical translation, we formed an international consortium dedicated to large-scale data sharing and analytics across expert groups. We show marked interconnectivity between six independent classification systems coalescing into four consensus molecular subtypes (CMSs) with distinguishing features: CMS1 (microsatellite instability immune, 14%), hypermutated, microsatellite unstable and strong immune activation; CMS2 (canonical, 37%), epithelial, marked WNT and MYC signaling activation; CMS3 (metabolic, 13%), epithelial and evident metabolic dysregulation; and CMS4 (mesenchymal, 23%), prominent transforming growth factor–β activation, stromal invasion and angiogenesis. Samples with mixed features (13%) possibly represent a transition phenotype or intratumoral heterogeneity. We consider the CMS groups the most robust classification system currently available for CRC—with clear biological interpretability—and the basis for future clinical stratification and subtype-based targeted interventions.
Subfields: Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/05d6eec2f0cb8fcd62dba7692f67bbbb2a298b50
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
- E. Batlle
- J. Massagué
- John N. Weinstein
- J. Bellmunt
- Fortunato Ciardiello
- R. Weinberg
- D. Pattabiraman
- Arthur W. Lambert
In Pathology and Forensic Medicine
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, neutral): “Unique subtypes are characterised by accumulation of distinct genetic and epigenetic alterations (DNA methylation), differing slightly from colon cancer [8, 9].”
- CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models (2017, methodology): “Here, we demonstrate that CMScaller can robustly classify also CRC organoids and PDXs, and outperforms the original CMSclassifier in seven publicly available datasets, including 26 15 and 22 organoids 16 , 40 14 , 37 28 , 51 29 and 244 20 PDX models, as well as a dataset of 131 27 cell lines.”
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “Subsequently, an international consortium dedicated to large-scale data sharing and analytics has recently provided a robust and unified classification, defining four different subtypes: CMS1 (MSI Immune), hypermutated, microsatellite unstable, with strong immune activation; CMS2 (Canonical), epithe”
- Molecular profiling for precision cancer therapies (2020, positive): “pression arrays are used to provide consensus molecular subtyping of colorectal cancer [110].”